Publications

 


  • 428. Interval cancers in the Antwerp European randomised study of screening for prostate cancer study, using a 6 year screening interval

    Nelen V, Thys G, Hermans A, D’Hooge K, Dourcy-Belle-Rose B, Coebergh J-W, Roobol M, Denis L, 2010

    Journal: Eur J Cancer
    Reference: 46(2010):3090-3094.

    paper

  • 427. Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer

    Boevee SJ, Venderbos LDF, Tammela TLJ, Nelen V, Ciatto S, Kwiatkowski M, Paez A, Malavaud B, Hugosson J, Roobol MJ, 2010

    Journal: Eur J Cancer
    Reference: 46(2010):3082-3089.

    paper

  • 426. Deciding on PSA-screening – Quality of current consumer information on the Internet

    Korfage IJ, van den Bergh RCN, Essink-Bot M-L, 2010

    Journal: Eur J Cancer
    Reference: 46(2010):3073-3081.

    paper

  • 425. Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European Randomized Study of Screening for Prostate Cancer

    Laurila M, van der Kwast T, Bubendorf L, di Lollo S, Pihl CG, Ciatto S, Hugosson J, Määttänen L, Roobol MJ, Kujala PM, 2010

    Journal: Eur J Cancer
    Reference: 46(2010):3068-3072.

    paper

  • 424. Blinded and uniform causes of death verification in cancer screening: A major influence on the outcome of a prostate cancer screening trial?

    Otto SJ, van Leeuwen PJ, Hoekstra JW, Merckelbach JW, Blom JHM, Schröder FH, Roobol MJ, de Koning HJ, 2010

    Journal: Eur J Cancer
    Reference: 46(2010):3061-3067.

    paper

  • 423. PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer

    Otto SJ, Moss SM, Määttänen L, Roobol MJ, Zappa M, Nelen V, Kwiatkowski M, Villers A, Hugosson J, Berenguer Sanchez A, de Koning HJ, 2010

    Journal: Eur J Cancer
    Reference: 46(2010):3053-3060.

    paper

  • 422. Prostate cancer incidence and mortality trends in 37 European countries: An overview

    Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A, 2010

    Journal: Eur J Cancer
    Reference: 46 (2010):3040-3052

    paper

  • 421. Foreword: Meeting the challenge of prostate cancer

    Auvinen A, de Koning HJ, Coebergh JW, 2010

    Journal: Eur J Cancer
    Reference: 46 (2010):3037-3039.

    paper

  • 420. Reply to David Connolly, Rachel Hutton, Patrick F. Keane’s Letter to the Editor re: Monique J. Roobol, Fritz H. Schröder, Pim van Leeuwen, et al. Performance of the Prostate Cancer Antigen 3 (PCA3) Gene and Prostate-Specific Antigen in Prescreened Men: Exploring the Value of PCA3 for a First-line Diagnostic Test.

    Roobol MJ, 2010

    Journal: Eur Urol
    Reference: 14-12-07

    paper

  • 419. Is Prostate Cancer Screening Bad or Good? Summary of a Debate at the Innovation in Urology Meeting, September 17-19, 2010, Milan, Italy.

    Roobol MJ, 2010

    Journal: Eur Urol
    Reference: Oct 26

    paper

  • 418. No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer.

    Carlsson SV, Holmberg E, Moss SM, Roobol MJ, Schröder FH, Tammela TL, Aus G, Auvinen AP, Hugosson J., 2011

    Journal: BJUI
    Reference: Jun;107(12):1912-7.

    paper

  • 417. Performance of Prostate Cancer Antigen 3 (PCA3) and Prostate-Specific Antigen in Prescreened Men: Reproducibility and Detection Characteristics for Prostate Cancer Patients with High PCA3 Scores (>=100).

    Roobol MJ, Schröder FH, van Leenders GL, Hessels D, van den Bergh RC, Wolters T, van Leeuwen PJ., 2010

    Journal: Eur Urol
    Reference: 58(2010):893-98.

    paper

  • 416. Balancing the harms and benefits of early detection of prostate cancer.

    van Leeuwen PJ, Connolly D, Tammela TL, Auvinen A, Kranse R, Roobol MJ, Schroder FH, Gavin A., 2010

    Journal: Cancer
    Reference: 15;116(20):4857-65.

    paper

  • 415. The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.

    Vickers AJ, Cronin AM, Roobol MJ, Hugosson J, Jones JS, Kattan MW, Klein E, Hamdy F, Neal D, Donovan J, Parekh DJ, Ankerst D, Bartsch G, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Freedland SJ, Moreira DM, Schröder FH, Lilja H, 2010

    Journal: Clin Cancer Reserach
    Reference: Sep 1;16(17):4374-81

    paper

  • 414. Words of wisdom. Re: Estimating the benefits of PSA screening.

    Roobol MJ, Schröder FH., 2010

    Journal: Eur Urol
    Reference: Jan;57(1):175-6

    paper

  • 413. Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.

    Wever EM, Draisma G, Heijnsdijk EA, Roobol MJ, Boer R, Otto SJ, de Koning HJ., 2010

    Journal: JNCI
    Reference: Mar 3;102(5):352-5

    paper

  • 412. The implementation of screening for prostate cancer.

    van Leeuwen PJ, van Vugt HA, Bangma CH., 2010

    Journal: Prostate Cancer Prostatic Dis.
    Reference: Sep;13(3):218-27.

    paper

  • 411. Risk factors: Increased risk of suicide after prostate cancer diagnosis.

    van Leeuwen PJ, Schröder FH., 2010

    Journal: Nat Rev Urol
    Reference: Jul;7(7):369-70.

    paper

  • 410. Why do men opt out of prostate-cancer screening? Attitudes and perception among participants and non-participants of a screening trial.

    Malmi H, Ruutu M, Määttänen L, Stenman UH, Juusela H, Tammela TL, Auvinen A., 2010

    Journal: BJUI
    Reference: Aug;106(4):472-7.

    paper

  • 409. Prostate-Specific Antigen (PSA) Isoform p2PSA in Combination with Total PSA and Free PSA Improves Diagnostic Accuracy in Prostate Cancer Detection.

    Jansen FH, van Schaik RH, Kurstjens J, Horninger W, Klocker H, Bektic J, Wildhagen MF, Roobol MJ, Bangma CH, Bartsch G., 2010

    Journal: Eur Urol
    Reference: 57(6):921-7

    paper

  • 408. A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands.

    Gupta A, Roobol MJ, Savage CJ, Peltola M, Pettersson K, Scardino PT, Vickers AJ, Schröder FH, Lilja H., 2010

    Journal: Br J cancer
    Reference: 103(5):708-14

    paper

  • 407. Should prostate-specific antigen screening be offered to asymptomatic men?

    van Vugt HA, Bangma CH, Roobol MJ., 2010

    Journal: Expert Rev Anticancer Ther.
    Reference: Jul;10(7):1043-53.

    paper

  • 406. Prostate Specific Antigen Velocity Does Not Aid Prostate Cancer Detection in Men With Prior Negative Biopsy.

    Vickers AJ, Wolters T, Savage CJ, Cronin AM, O'Brien MF, Roobol MJ, Aus G, Scardino PT, Hugosson J, Schröder FH, Lilja H., 2010

    Journal: J Urol
    Reference: Sep;184(3):907-912.

  • 405. Reply from Authors re: Vincenzo Ficarra, Giacomo Novara, Filiberto Zattoni, The role of the prostate cancer antigen 3 (PCA3) test for the diagnosis of prostate cancer in the era of opportunistic prostate-specific antigen screening.

    Roobol MJ, Schröder FH, 2010

    Journal: Eur Urol
    Reference: Oct;58(4):481.

    paper

  • 404. The Role of the Prostate Cancer Antigen 3(PCA3)Test for the Diagnosis of Prostate Cancer in the Era of Opportunistic Prostate-Specific Antigen Screening

    Ficarra V, Novara G,Zattoni F, 2010

    Journal: Eur Urol
    Reference: Oct;58(4):475-81.

    paper

  • 403. Performance of the Prostate Cancer Antigen 3 (PCA3) Gene and Prostate-Specific Antigen in Prescreened Men: Exploring the Value of PCA3 for a First-line Diagnostic Test.

    Roobol MJ, Schröder FH, van Leeuwen P, Wolters T, van den Bergh RC, van Leenders GJ, Hessels D., 2010

    Journal: Eur Urol
    Reference: 58(4):475-81.

    paper

  • 402. Screening for prostate cancer: have we resolved the controversy?

    Zhu X, Roobol MJ, Schröder FH., 2010

    Journal: Curr Opin Support Palliat Care.
    Reference: Sep;4(3):121-6.

    paper

  • 401. The REDUCE trial

    Schröder FH, Roobol MJ., 2010

    Journal: Eur Urol
    Reference: 58(2):253-5

  • 400. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.

    Vickers A, Cronin A, Roobol M, Savage C, Peltola M, Pettersson K, Scardino PT, Schröder F, Lilja H., 2010

    Journal: JCO
    Reference: May 20;28(15):2493-8

    paper

  • 399. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.

    Vickers AJ, Cronin AM, Roobol MJ, Savage CJ, Peltola M, Pettersson K, Scardino PT, Schröder FH, Lilja H., 2010

    Journal: Clin Cancer Research
    Reference: Jun 15;16(12):3232-9

    paper

  • 398. Results of the three rounds of the Finnish Prostate Cancer Screening Trial – the incidence of advanced cancer is decreased by screening

    Kilpeläinen TP, Auvinen A,Määttänen L, Kujala P, Ruutu M, Stenman U-H,Tammela TLJ, 2010

    Journal: Int J cancer
    Reference: 27(7):1699-705

    paper

  • 397. Effect of the correction for non-compliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section rotterdam).

    Kerkhof M, Roobol MJ, Cuzick J, Sasieni P, Roemeling S, Schröder FH, Steyerberg EW., 2010

    Journal: Int J cancer
    Reference: 127(11):2639-44

    paper

  • 396. Prostate cancer incidence rates have started to decrease in central Italy

    Crocetti E, Ciatto S, Buzzoni C, Zappa M, 2010

    Journal: J Med Screening
    Reference: 17:50–51

    paper

  • 395. ERSPC and PLCO Prostate Cancer Screening Studies: What Are the Differences?

    Schröder FH, Roobol MJ, 2010

    Journal: Eur Urol
    Reference: Jul;58(1):46-52

    paper

  • 394. Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees.

    Bergdahl AG, Aus G, Lilja H, Hugosson J., 2009

    Journal: Cancer
    Reference: 15;115(24):5672-9.

    paper

  • 393. False-positive screening results in the Finnish prostate cancer screening trial.

    Kilpeläinen TP, Tammela TL, Määttänen L, Kujala P, Stenman UH, Ala-Opas M, Murtola TJ, Auvinen A., 2010

    Journal: Br J Cancer
    Reference: Feb 2;102(3):469-74

    paper

  • 392. Prostate cancer and PSA among statin users in the finnish prostate cancer screening trial.

    Murtola TJ, Tammela TL, Määttänen L, Huhtala H, Platz EA, Ala-Opas M, Stenman UH, Auvinen A, 2010

    Journal: Int J cancer
    Reference: Oct 1;127(7):1650-9

    paper

  • 391. PSA screening – a review of recent studies

    Schröder FH, 2009

    Journal: Eur J Cancer
    Reference: 45 Suppl 1:402-4

    paper

  • 390. Is Delayed Radical Prostatectomy in Men With Low-Risk Screen-Detected Prostate Cancer Associated With a Higher Risk of Unfavorable Outcomes?

    van den Bergh RCN, Steyerberg EW, Khatami A, Aus G, Pihl CG, Wolters T, van Leeuwen PJ, Roobol MJ, Schröder FH, Hugosson J, 2010

    Journal: Cancer
    Reference: Mar 1;116(5):1281-90

    paper

  • 389. Informed decision making on PSA testing for the detection of prostate cancer: An evaluation of a leaflet with risk indicator

    van Vugt HA, Roobol MJ, Venderbos LDF, Joosten-van Zwanenburg E, Essink-Bot M-L, Steyerberg EW, Bangma CH, Korfage IJ, 2010

    Journal: EJC
    Reference: 46:669-677

    paper

  • 388. Oomens EHGM, Rannikko A, Roemeling S, Steyerberg EW, Roobol MJ, Schröder FH, Bangma CH Short-term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study

    van den Bergh RCN, Vasarainen H, van der Poel HG, Vis-Maters JJ, Rietbergen JBW, Pickles T, Cornel EB, Valdagni R, Jaspars JJ, van der Hoeven J, Staerman F, 2009

    Journal: BJUI
    Reference: 14-01-07

    paper

  • 387. Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit

    van Leeuwen PJ, Connolly D, Gavin A, Roobol MJ, Black A, Bangma CHa, Fritz H. Schro¨der, 2010

    Journal: EJC
    Reference: 3 7 7 –3 8 3

    paper

  • 386. Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer

    Heijnsdijk EAM,der Kinderen A,Wever EM, Draisma G, Roobol MJ, de Koning HJ, 2009

    Journal: BJC
    Reference: 101, 1833 – 1838

    paper

  • 385. False-negative Prostate Needle Biopsies: Frequency, Histopathologic Features, and Follow-up

    Wolters T, van der Kwast ThH, Vissers CJ, Bangma CH, Roobol MJ, Schröder FH, van Leenders GJLH, 2010

    Journal: Am J Surg Pathol
    Reference: 34:35–43

    paper

  • 384. Eleven-Year Outcome of Patients with Prostate Cancers Diagnosed During Screening After Initial Negative Sextant Biopsies

    Schröder FH, van den Bergh RCN, Wolters T, van Leeuwen PJ, Bangma CH, van der Kwast Th H, Roobol MJ, 2010

    Journal: Eur Urol
    Reference: 57(2):256-66

    paper

  • 383. A Risk-Based Strategy Improves Prostate-Specific Antigen–Driven Detection of Prostate Cancer

    Roobol MJ, Steyerberg EW, Kranse R,Wolters T,van den Bergh RCN, Bangma CH, Schröder FH, 2010

    Journal: Eur Urol
    Reference: 57:79-85

    paper

  • 382. Should Pathologists Routinely Report Prostate Tumour Volume? The Prognostic Value of Tumour Volume in Prostate Cancer

    Wolters T, Roobol MJ, van Leeuwen PJ, van den Bergh RCN, Hoedemaeker RF, van Leenders GJLH, Schröder FH, van der Kwast ThH, 2009

    Journal: Eur Urol
    Reference: XX-XX

  • 381. Prostate-Specific Antigen Velocity for Early Detection of Prostate Cancer: Result from a Large, Representative, Population-based Cohort

    Vickers AJ, Wolters T, Savage CJ, Cronin AM,O’Brien MF, Pettersson K, Roobol MJ, Aus G, Scardino PT, Hugosson J, Schröder FH, Lilja H, 2009

    Journal: Eur Urol
    Reference: 56: 753-760

    paper

  • 380. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC

    Wolters T,Roobol MJ, Steyerberg EW, van den Bergh RCN, Bangma CH, Hugosson J, Ciatto S, Kwiatkowski M, Villers A, Lujan M, Nelen V, Tammela TLJ, Schröder FH, 2010

    Journal: Int J cancer
    Reference: january

    paper

  • 379. A Framework for the Identification of Men at Increased Risk for Prostate Cancer

    Roobol MJ, Schröder FH,Crawford D, Freedland SJ,Sartor O, Fleshner N, 2009

    Journal: J Urol
    Reference: Vol. 182, 2112-2122

    paper

← PreviousNext →